Metrics to compare | XLS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipXLSPeersSector | |
|---|---|---|---|---|
P/E Ratio | −4.6x | 5.1x | −0.4x | |
PEG Ratio | 0.03 | 0.04 | 0.00 | |
Price/Book | 0.3x | 1.9x | 2.6x | |
Price / LTM Sales | 357.3x | 3.6x | 3.0x | |
Upside (Analyst Target) | 184.1% | 4.3% | 50.8% | |
Fair Value Upside | Unlock | −2.8% | 9.4% | Unlock |
Xlife Sciences AG focuses on the development and commercialization of research projects in the life sciences sector. The company’s project covers technology platforms, biotechnology/therapies, medical technology, and artificial intelligence/digital health areas that focuses on identifying new therapeutic approaches and biomarkers for common diseases based on human genetic data; and offers clinical research services. It also develops novel treatment options in specific indication areas; focuses in the areas of medical technology to develop innovative methods for diagnosing illnesses and/or patient monitoring; and deploys artificial intelligence to improve diagnostic methods and/or processes in the field of biotechnology. Xlife Sciences AG was founded in 2019 and is headquartered in Zurich, Switzerland.